Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07036133 | Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment(SPI-FOL-102) | recruiting | Phase 1 | 24 | Acrotech Biopharma Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07328217 | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 203 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 11, 2026 |
| clinicaltrials |
| NCT04078295 | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 125 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04822688 | Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues | completed | — | 141 | Thomas Jefferson UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06634849 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | recruiting | Phase 1 / Phase 2 | 30 | Pathios Therapeutics Pty LtdINDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05620017 | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection | recruiting | Phase 1 | 182 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06331559 | Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors | terminated | Phase 1 | 13 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06534190 | CD8 PET Imaging in Metastatic Solid Tumours | recruiting | Phase 2 | 30 | University Medical Center GroningenOTHER | 3 | Feb 9, 2026 | clinicaltrials |
| NCT07396090 | Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors | not yet recruiting | N/A | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 9, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04932525 | Gustave Roussy Cancer Profiling(STING) | recruiting | N/A | 20,000 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05359237 | Vincristine Pharmacokinetics in Infants | active not recruiting | — | 83 | Children's Oncology GroupNETWORK | 3 | Feb 6, 2026 | clinicaltrials |
| NCT05982873 | Expanded Access to Telisotuzumab Adizutecan | available | — | — | AbbVieINDUSTRY | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07391644 | A Study of JSKN027 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 250 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07392736 | A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 228 | Advenchen Laboratories, LLCINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03465592 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | recruiting | Phase 1 / Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05701527 | A Study of EBC-129 in Advanced Solid Tumours | recruiting | Phase 1 | 98 | EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesOTHER_GOV | 3 | Feb 5, 2026 | clinicaltrials |
| NCT07359066 | An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Shanghai SciBrunch Therapeutics Co., Ltd.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05478486 | Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours | completed | Phase 1 | 7 | Godavari Biorefineries LimitedOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05892718 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | recruiting | Phase 1 | 80 | FBD Biologics LimitedINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
| NCT06771622 | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 500 | FBD Biologics LimitedINDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07327632 | This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors | recruiting | Early Phase 1 | 300 | Innovent Biologics Technology Limited (Shanghai R&D Center)INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07382531 | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385950 | Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors | not yet recruiting | — | 100 | Zhongnan HospitalOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05352750 | Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 42 | Sonnet BioTherapeuticsINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05372367 | A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor | completed | Phase 1 | 33 | Boehringer IngelheimINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT06772090 | Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies | not yet recruiting | N/A | 40 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT05744427 | Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 725 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 1 | 42 | Prelude TherapeuticsINDUSTRY | 6 | Feb 2, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07215637 | Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 60 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07381179 | Voices: Messages of Wisdom and Hope in the Face of Illness | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT05584449 | Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 60 | Mayo ClinicOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06682039 | Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors | completed | N/A | 70 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT06809114 | FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors | recruiting | Phase 1 | 83 | Axcynsis Therapeutics Pte LtdINDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07377591 | A Study of HDM2006 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 48 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | Pheon TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06592092 | Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors | completed | N/A | 3 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06644300 | Study of BM230 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 123 | Suzhou Biomissile Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 29, 2026 | clinicaltrials |
| NCT07148128 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 110 | Auricula Biosciences Inc.INDUSTRY | 3 | Jan 29, 2026 | clinicaltrials |
| NCT07375446 | Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome | not yet recruiting | — | 300 | Peking University Third HospitalOTHER | 0 | Jan 29, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Feb 11, 2026source: clinicaltrials